AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

May 24, 2021

AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease

NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week® (DDW) Virtual Conference 2021 showed significantly greater proportions of patients with moderately to severely active Crohn's disease treated with both doses of investigational risankizumab (600 mg or 1200 mg) met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo (p<0.001 for each) in two Phase 3 induction studies.1 This is the first presentation of data from these two studies, ADVANCE and MOTIVATE, following the announcement of top-line data earlier this year.

May 24, 2021

The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis

NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating RINVOQ® (upadacitinib) in adults and adolescents with moderate to severe atopic dermatitis who were candidates for systemic treatment. The results were published in two separate manuscripts as part of the May 22, 2021 issue of The Lancet. 

May 20, 2021

AbbVie to Present at the UBS Global Healthcare Virtual Conference

NORTH CHICAGO, Ill., May 20, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 11:00 a.m. Central time.

May 19, 2021

AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses

NORTH CHICAGO, Ill., May 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the virtual European Hematology Association (EHA) congress (June 9-17).

May 12, 2021

AbbVie to Present at the RBC Capital Markets Global Healthcare Conference

NORTH CHICAGO, Ill., May 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 3:50 p.m. Central time.

May 10, 2021

Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio

IRVINE, Calif. and HOUSTON, May 10, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and Soliton (NASDAQ: SOLY) today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONICTM, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The acquisition of Soliton expands and complements Allergan Aesthetics' Body Contouring treatment portfolio which includes CoolSculpting® Elite.

Apr 30, 2021

AbbVie Reports First-Quarter 2021 Financial Results

NORTH CHICAGO, Ill., April 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021.

Apr 27, 2021

Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting

NORTH CHICAGO, Ill., April 27, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting (May 1-7).

Apr 23, 2021

AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

NORTH CHICAGO, Ill., April 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VENCLYXTO® (venetoclax) in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. The positive CHMP opinion is a scientific recommendation for marketing authorization to the European Commission (EC), which is expected to deliver its final decision on VENCLYXTO combination therapy for use in AML in the first half of 2021.

Apr 07, 2021

AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA

NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI® (risankizumab, 150 mg) to the European Medicines Agency (EMA) for the treatment of adults with active psoriatic arthritis.1 The submissions were supported by two pivotal Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated SKYRIZI in adults with active psoriatic arthritis including those who had responded inadequately or were intolerant to biologic therapy and/or non-biologic disease-modifying anti-rheumatic drugs (DMARDs).1